^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    sonesitatug vedotin (AZD0901)

    i
    Company:
    AstraZeneca, Keymed Biosciences, Lepu Med
    Drug class:
    Microtubule inhibitor, CLDN18.2-targeted antibody-drug conjugate
    Related drugs:
    Apply
    Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (GEMINI-Gastric) (NCT05702229)
    Phase 2
    AstraZeneca
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    01/16/2023
    Primary completion :
    01/30/2026
    Completion :
    01/28/2027
    CLDN18
    |
    5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 (KYM901) (NCT04805307)
    Phase 1
    Keymed Biosciences Co.Ltd
    Completed
    Last update posted :
    02/12/2025
    Initiation :
    12/24/2020
    Primary completion :
    04/05/2024
    Completion :
    04/05/2024
    CLDN18
    |
    CLDN18.2 positive
    |
    sonesitatug vedotin (AZD0901)
    AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 (CLARITY-PanTumor01) (NCT06219941)
    Phase 2
    AstraZeneca
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    12/13/2023
    Primary completion :
    05/02/2025
    Completion :
    01/19/2027
    CLDN18
    |
    CLDN18.2 expression
    |
    gemcitabine • 5-fluorouracil • leucovorin calcium • sonesitatug vedotin (AZD0901) • Onivyde (nanoliposomal irinotecan)